Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry

(2019) Edoardo Francini et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity

(2018) Marka R. Crittenden et al.   Scientific Reports

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

(2018) Wassim Abida et al.   JAMA Oncology

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

(2017) Tomasz M. Beer et al.   JOURNAL OF CLINICAL ONCOLOGY

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

QuPath: Open source software for digital pathology image analysis

(2017) Peter Bankhead et al.   Scientific Reports

Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming

(2016) M. E. Rodriguez-Ruiz et al.   CANCER RESEARCH

The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer

(2015) H. Gevensleben et al.   CLINICAL CANCER RESEARCH

Myeloid-Derived Cells in Tumors: Effects of Radiation

(2015) Ralph E. Vatner et al.   SEMINARS IN RADIATION ONCOLOGY

Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice

(2015) Luís Felipe Campesato et al.   Oncotarget

Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer

(2014) Manja Idorn et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

PIM Kinase Inhibitor AZD1208 for Treatment of MYC-Driven Prostate Cancer

(2014) Austin N. Kirschner et al.   JNCI-Journal of the National Cancer Institute

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

(2014) Eugene D Kwon et al.   LANCET ONCOLOGY

Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?

(2014) C. Tang et al.   Cancer Immunology Research

Current Status and Recommendations for the Future of Research, Teaching, and Testing in the Biological Sciences of Radiation Oncology: Report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, Executive Summary

(2013) Paul E. Wallner et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of a castrate resistant transplant tumor model of prostate cancer

(2011) Leigh Ellis et al.   PROSTATE